Zura Bio initiated with an Outperform at Leerink

Leerink initiated coverage of Zura Bio (ZURA) with an Outperform rating and $15 price target The company has assembled an “impressive collection of immunology assets against a combination of de-risked and emerging targets,” the analyst tells investors in a research note. The firm thinks there are “many ways to win here” and is most excited by the potential for Zura’s lead asset tibulizumab in systemic sclerosis. It expects investor appreciation for the Zura story will continue to increase as 2026 data readouts for tibulizumab approach.